NCT02395913View on ClinicalTrials.gov

Compare Safety and Pharmacokinetic Properties of Surfolase Capsule(Acebrophylline 100mg) and Surfolase CR(200mg)

PHASE1CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Healthy Male
Interventions
DRUG

Surfolase capsule (100mg)

Surfolase capsule one capsule twice one days fasting administration

DRUG

Surfolase CR (200mg, T1)

one tablet once one days fasting administration.

DRUG

Surfolase CR (200mg, T3)

one tablet once one days fasting administration.

DRUG

Surfolase CR (200mg, T4)

one tablet once one days fasting administration.

Sponsors
All Listed Sponsors
lead

Hyundai Pharmaceutical Co., LTD.

INDUSTRY